CymaBay Therapeutics Announces Departure of Chief Medical Officer

NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that Pol Boudes, M.D., Chief Medical Officer, will be leaving the company on September 30, 2019 to explore other opportunities.? CymaBay has initiated a formal search for his replacement.

Click to view original post